



Hope Therapeutics

an **NRx** Daughter Co.

Corporate Overview

Hope. Science. Life.

October 2024



Safe Harbor Statement

This presentation (this “Presentation”) is provided for informational purposes only. No representations or warranties, express or implied are given in, or in respect of, this Presentation. To the fullest extent permitted by law in no circumstances will Hope Therapeutics, Inc. (“Hope Tx”) or any of its subsidiaries, stockholders, affiliates, representatives, partners, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this Presentation, its contents, its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of Hope Tx. Viewers of this Presentation should each make their own evaluation of Hope Tx and of the relevance and adequacy of the information and should make such other investigations as they deem necessary.

Forward-Looking Statements: Certain statements included in this Presentation include “forward-looking statements” within the meaning of the federal securities laws with respect to Hope Tx and its business, including without limitation, the drugs under development by NRx, the markets in which it operates, and Hope Tx’s expectations with respect to future performance. Hope Tx’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements generally are identified by the words “aspire,” “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “will be,” “will continue,” “will likely result,” “could,” “should,” “believe,” “predicts,” “potential,” “continue,” “future,” “opportunity,” “strategy,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside of Hope Tx’s control and are difficult to predict. Factors that may cause such differences may include the future financial and operating results of NRx; inherent uncertainty associated with the FDA approval process; changes in applicable laws or regulations; the possibility that Hope Tx may be adversely affected by economic, business, and/or competitive factors; the impact of COVID-19 or other adverse public health developments. Hope Tx cautions that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Hope Tx does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Industry and Market Data: Industry and market data used in this Presentation have been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. NRx has not independently verified the data obtained from these sources and cannot assure you of the data’s accuracy or completeness. This data is subject to change without notice.

Trademarks: Hope Therapeutics and related marks are registered trademarks or trademark applications of, or are otherwise owned or used by, Hope Tx or its affiliates. Any trademarks, trade names or service marks of other companies appearing herein are the property of their respective owners. Solely for convenience, the trademarks, service marks and trade names referred to in this Presentation may appear without the ®, TM or SM symbols, but the absence of such references does not indicate the registration status of the trademarks, service marks and trade names and is not intended to indicate, in any way, that Hope Tx will not assert, to the fullest extent under applicable law, rights to such trademarks, service marks and trade names.

Caution against inferences: This Presentation is not a comprehensive presentation of NRx development programs and will discuss selected products and advances. The information presented is based on our current understanding of biotechnology development and marketing programs that are subject to change as science evolves. In particular, no inferences should be drawn about programs that are not mentioned or discussed in this or any investor presentation offered by Hope Tx.



Suicidality is a National Crisis: We Provide **HOPE**

Suicidality kills ~50,000 Americans every year
Still seen as a hopeless cause, and NOT a treatable medical condition



Over
49,000
people died by
suicide in 2022



1 death every
11 minutes


Many adults think about
suicide or attempt suicide

13.2 million
Seriously thought about suicide

3.8 million
Made a plan for suicide

1.6 million
Attempted suicide


It often takes our best and brightest



A Medical Breakthrough for Suicidal Depression

A breakthrough treatment that is poorly implemented today

**Only FDA-approved therapy is
Electro-Convulsive Therapy
(ECT)**



**IV Ketamine reduces suicidal
ideation and behavior within
hours in many patients**



Esketamine is currently approved for treatment of depression in patients at risk of self-harm but may not be used in patients with bipolar depression.




Ketamine is dramatically effective but cannot be used continuously

TMS, Digital Therapeutics and Supportive Therapy are needed to extend the lifesaving effect

Transcranial Magnetic Stimulation (TMS) alters brain pathways and extends the effect of Ketamine



Digital Therapeutics were developed in the military and shown to reduce stress and depression



The First National Network devoted to Suicide Prevention

A trailblazing precision psychiatry network providing interventional pharmaceutical therapy, TMS, Digital Therapeutics, and supportive therapy for suicidal depression, PTSD, anxiety, OCD and more.

Our Mission

To offer state of the art **interventional psychiatry** care to render suicidal depression and PTSD curable diseases with overnight results, offering HOPE to patients and families without stigma

Our Vision

When people tell the story of their mental health journey in the US, they and their family end the story by saying:

"We went to HOPE and were cured."



HOPE Continuum of Care: Beyond Ketamine

- 1** The dramatic pharmacologic effect of Ketamine lasts for < 1 week
- 2** Patients need ongoing support from therapists who understand the interventional model
- 3** Our lead clinics have shown that Transcranial Magnetic Stimulation extends the Ketamine effect (FDA approved)
- 4** Research sponsored by DARPA demonstrates measurable benefit of Digital Therapeutic approach in reducing depression and stress
- 5** Powerful opportunity to differentiate Hope clinics from alternatives

*Digital Therapeutics are regulated by the FDA as medical devices and may not make claims of health benefit without FDA clearance or approval



Breakthrough Treatments require a National Umbrella

To bridge the quality chasm

A national Patient Relationship Management (PRM) system,

AI-driven Telepsychiatry, Common Protocols, and Proven Outcomes



HOPE Therapeutics Four Phase Path to Success:

Buying clinics at EBITDA multiples and assembling an enterprise worth 15x earnings

Acquire profitable clinics, Add a nationwide umbrella, Add new lines of business to double profit

1. Acquire and integrate 30+ existing, profitable Ketamine clinics through 2025

- Debt finance is committed to acquire at market EBITDA multiples
- Target \$100 million/yr run-rate with positive EBITDA
- **Make good clinics great:** increase revenues via addition of additional business lines and access, grow EBITDA via product mix, efficiencies and operational optimization

2. Build a national brand with a nationwide Patient Relationship Management (PRM) umbrella

- Today there is a vacuum, and patients don't know who to call
- HOPE provides the patient portal that will get patients into care in any city in the US
- Creates a national footprint of owned and partnered facilities

3. Augment Ketamine therapy with TMS and Digital Therapeutics

- TMS and Digital Therapeutics augment the effect of Ketamine
- Improved outcomes as well as accretive to clinic operations

4. Develop proprietary products to improve patient outcomes and profitability

- Oral therapeutics currently in development
- Ketamine analogs currently in development



Establishing Hope's Clinical Foundations

Acquire, integrate, and expand ~30 behavioral health sites in coming 18 months


- Stage 1:** Acquisition of 15–18 industry-leading Behavioral Health Clinics by mid-2025
~12 clinics already identified in target regions – now in active acquisition
- Stage 2:** Double the clinical network with acquisition of 15–18 additional full-service mental health clinics – vetting a list of 20+ clinics in the pipeline for advancement to due diligence
- Stage 3:** Starting in ~2026, initiate a Hub/Spoke clinical network in individual regions by attracting additional provider-owned clinics while expanding the footprint of portfolio clinics to new sites



HOPE Clinic Selection Criteria

Prioritizing:

- Full-service mental health practices treating depression, PTSD, Anxiety, and more
- Strong staff retention
- Strong patient and provider satisfaction
- Clinics with strong ARR and positive EBITDA
- Potential to increase both revenue / earnings rate by >10% in first year for portfolio clinics
- Non-CPOM states favored, starting with **Fl & Va**
- Expand to franchise network via MSO partnerships



Projected valuation/acquisition cost: Market EBITDA multiples

5,000+ outpatient mental health/psych clinics in the US. 800+ already offering Ketamine therapy



Disrupting the Traditional PE Model to Drive Growth

Traditional PE is breaking mental healthcare delivery

- Traditional PE model of cutting costs and curtailing staff is limiting both quality of care and access, even as their behavioral health networks expand locations
- Deep dissatisfaction amongst most acquired entities under PE leadership
- Cost-cutting measures that reduce quality of care are both harmful and unnecessary when opportunity for growth and expansion is present
- Current state-level focus on curtailing PE acquisition of healthcare practices

Hope's acquisition and integration model drives commercial success by improving clinical success

- Focus on adding psychiatrist-driven care to current “infusion-only” centers, expanding clinical offerings to new procedures, services, and digital engagements to enrich patient experience
- Increasing provider staff to meet growing patient demand and reduce wait times
- Increasing referral volume to clinical procedures through expanding provider staff, marketing, community partnerships at regional and national level



Leadership Team



Matthew Duffy
Co-CEO

30+ years of biotechnology-related business and investment banking expertise. Business leadership roles at Pfizer and Medimmune. Investment banking and research roles at Roberts Mitani, LifeSci Advisors, and Laidlaw. Series 7, 63, and 65 Securities Licenses.



Jonathan Javitt, MD, MPH
Co-CEO & Chairman

40 years in pharmaceutical and medical device development. Blockbuster drug and device development programs with Allergan, Eyetech, Merck, Novartis, Pfizer, and Pharmacia. Advisor to four White House administrations.



To Be Announced, MD, PhD
Chief Medical & Innovation Officer

Founder of [leading Interventional Psychiatry Clinic] in US, and one of the first academic leaders to administer Ketamine for depression.



Rick Panicucci, PhD
Chief Technology Officer

25 years manufacturing leadership. Head of CCP, Novartis. VP of Manufacturing, WuXi Apptec. Chief Technology Officer, Bridge Bio.



Zachary Javitt
VP Business Development & Brand Strategy

Over 10 years of market development and product development in Digital health and Biotech. Leadership in marketing and operational roles at NRx Pharmaceuticals and PillTracker. Business Development & M&A lead for Hope Clinics M&A



Richard Narido
CFO

Mr. Narido has more than 20 years of experience in accounting and finance, including in the CFO role. Companies include Lucira Health (acquired by Pfizer in 2023), Assembly Biosciences, Bio-Rad Laboratories, Novartis Vaccines and Diagnostics, and McKesson Corporation. Mr. Narido started his career with PricewaterhouseCoopers's Financial Audit and Assurance practice.



Scientific Advisory Board

Gerard Sanacora, PhD, MD – Chair

Professor of Psychiatry at Columbia University. Initial discovery on the role of NMDA antagonists in psychiatric disorders. More than 760 publications in the field. Inventor of the NRx patent portfolio

Marion Leboyer, MD, PhD – EU Principal Investigator

Professor of Psychiatry Inserm (Paris). More than 1300 publications related to clinical psychiatry and infectious / genetic triggers of psychiatric disease.

Andrew Nierenberg, MD – US Principal Investigator

Professor of Psychiatry at Harvard University, Director, Dauten Family Center for Bipolar Treatment Innovation. More than 875 publications in the field. Director of the national Patient Centered Outcomes Research Initiative in treatment of Bipolar Depression.

Philip Lavin, PhD – Lead Methodologist

NRx Lead Methodologist. Clinical Professor, Harvard Medical School and Harvard School of Public Health. FDA Special Government Employee in Statistics. More than 78 Drug and Medical Device Approvals and more than 350 scientific publications.



Hope Therapeutics Near-Term Investor Highlights:

Make Good Clinics Great

- **Acquisition and management of ~30+ Ketamine clinics through 2025**
 - Target \$100 million/yr run-rate with positive EBITDA
 - Starting with industry-leading mental health practices that set the standard and scale for future acquisitions; ongoing revenue and positive EBITDA
 - ***Make good clinics great***: increase revenues via offerings and access, grow EBITDA via product mix, efficiencies and operational optimization
- **Disciplined financing strategy**
 - Clinic acquisition:
 - Fair EBITDA multiples with performance based earn-outs
 - Cash via corporate bonds and/or other debt financing expected
 - IPO: planned as the company begins to scale & generate meaningful revenue
- **Building shareholder value**
 - Market value of clinics is largely based on EBITDA multiples
 - ***Growing total EBITDA, via increased integration of services, directly enhances shareholder value; debt financing avoids dilution***





Thank You

**For further information
Please contact:**

Matthew Duffy, Co-CEO
HOPE Therapeutics, Inc.
mduffy@hopetherapeutics.com

